Literature DB >> 19021300

Sialorrhoea and drooling in patients with Parkinson's disease: epidemiology and management.

Marcelo Merello1.   

Abstract

Although often less recognized than motor symptoms, non-motor effects represent an important source of disability for many parkinsonian patients. Of these non-motor symptoms, sialorrhoea, defined as the inability to control oral secretions resulting in excessive saliva accumulation in the oropharynx, constitutes perhaps one of the most bothersome and troubling problems, often causing social embarrassment and isolation. In patients with Parkinson's disease (PD), this symptom is thought to be due to restricted swallowing and dysfunction, rather than to hypersecretion of saliva. Only a few well designed studies have been conducted to determine the optimal treatment for sialorrhoea in PD. A combination of approaches appears to be necessary to obtain successful results.

Entities:  

Mesh:

Year:  2008        PMID: 19021300     DOI: 10.2165/0002512-200825120-00003

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  89 in total

1.  Assessment of salivary flow rate: biologic variation and measure error.

Authors:  Peter H Jongerius; Jacques van Limbeek; Jan J Rotteveel
Journal:  Laryngoscope       Date:  2004-10       Impact factor: 3.325

Review 2.  Physiology of swallowing.

Authors:  W J Dodds
Journal:  Dysphagia       Date:  1989       Impact factor: 3.438

3.  Three treatment approaches and clinical factors in the reduction of drooling.

Authors:  N Thomas-Stonell; J Greenberg
Journal:  Dysphagia       Date:  1988       Impact factor: 3.438

4.  Submandibular gland resection and bilateral parotid duct ligation as a management for chronic drooling in cerebral palsy.

Authors:  S R Brundage; W D Moore
Journal:  Plast Reconstr Surg       Date:  1989-03       Impact factor: 4.730

5.  Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial.

Authors:  Oliver Freudenreich; Lawrence Herz; Thilo Deckersbach; A Eden Evins; David C Henderson; Corinne Cather; Donald C Goff
Journal:  Psychopharmacology (Berl)       Date:  2005-10-14       Impact factor: 4.530

Review 6.  Gastrointestinal dysfunction in Parkinson's disease: frequency and pathophysiology.

Authors:  L L Edwards; E M Quigley; R F Pfeiffer
Journal:  Neurology       Date:  1992-04       Impact factor: 9.910

7.  Determination of variation of stimulated salivary flow rates.

Authors:  E M Ghezzi; L A Lange; J A Ship
Journal:  J Dent Res       Date:  2000-11       Impact factor: 6.116

8.  Detection of motor and non-motor symptoms of end-of dose wearing-off in Parkinson's disease using a dedicated questionnaire: a Belgian multicenter survey.

Authors:  Patrick Santens; Alain Maertens de Noordhout
Journal:  Acta Neurol Belg       Date:  2006-09       Impact factor: 2.396

9.  Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study.

Authors:  J Jankovic
Journal:  Ann Neurol       Date:  1982-01       Impact factor: 10.422

10.  Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism.

Authors:  Francesca Mancini; Roberta Zangaglia; Silvano Cristina; Maria Grazia Sommaruga; Emilia Martignoni; Giuseppe Nappi; Claudio Pacchetti
Journal:  Mov Disord       Date:  2003-06       Impact factor: 10.338

View more
  5 in total

Review 1.  Use of botulinum toxin in the neurology clinic.

Authors:  Erle C H Lim; Raymond C S Seet
Journal:  Nat Rev Neurol       Date:  2010-10-12       Impact factor: 42.937

Review 2.  Clinical features associated with drooling in Parkinson's disease.

Authors:  David Nascimento
Journal:  Neurol Sci       Date:  2021-01-14       Impact factor: 3.307

Review 3.  Drooling in Parkinson's disease: a review.

Authors:  Prachaya Srivanitchapoom; Sanjay Pandey; Mark Hallett
Journal:  Parkinsonism Relat Disord       Date:  2014-08-27       Impact factor: 4.891

4.  Gender-related differences in the burden of non-motor symptoms in Parkinson's disease.

Authors:  Pablo Martinez-Martin; Cristian Falup Pecurariu; Per Odin; Jacobus J van Hilten; Angelo Antonini; Jose M Rojo-Abuin; Vanderci Borges; Claudia Trenkwalder; Dag Aarsland; David J Brooks; Kallol Ray Chaudhuri
Journal:  J Neurol       Date:  2012-01-12       Impact factor: 4.849

5.  Incobotulinumtoxin A for Sialorrhea in Neurological Disorders: A Real-Life Experience.

Authors:  Javier Martínez-Poles; Velina Nedkova-Hristova; José Bernardo Escribano-Paredes; Sebastián García-Madrona; Elena Natera-Villalba; Carlos Estévez-Fraga; José Luis López-Sendón Moreno; Icíar Avilés-Olmos; Gema Sánchez Díaz; Juan Carlos Martínez Castrillo; Araceli Alonso-Canovas
Journal:  Toxins (Basel)       Date:  2018-05-28       Impact factor: 4.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.